Despite the wide range of drugs used in the pharmacotherapy of chronic pain, new substances are still being sought that perform as effectively or better than currently known analgesics. The analgesic effects of drugs that are already used in therapy for indications other than pain are also being sought. A new drug from the gabapentinoid group, mirogabalin, and reboxetine – an antidepressant from the selective norepinephrine reuptake inhibitor group are showing promise in the treatment of chronic pain, particularly neuropathic pain. This article provides a narrative review of the scientific reports published to date in this area using the aforementioned substances.